[F-18]MeFAMP PET

Phase 1

UUniversity of Alabama at Birmingham

[F-18]MeFAMP PET is one of 2 therapeutic programs targeting Recurrent Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent GliomaNot yet recruiting

Recurrent GliomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Recurrent Glioma

#DrugCompanyPhaseTrials

Balversa

Johnson & Johnson

Phase 2

1 2

[F-18]MeFAMP PET

UUniversity of Alabama at Birmingham

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Not yet recruiting

Recurrent Glioma

NCT05676489

Clinical

Trials by Indication[1]

Recurrent Glioma1 trial

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

Not yet recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05676489·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [F-18]MeFAMP PET. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [F-18]MeFAMP PET. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Alabama at Birmingham

[F-18]MeFAMP PET

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Recurrent Glioma1 trial

References

Drug Info

Quick Facts

Related News